Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB 1 receptor

British Journal of Pharmacology

Volumn 155, Issue 1, 2008, Pages 24-33

  Bosier, B ^a   Hermans, E ^a   Lambert, D M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Agonist selective trafficking of receptor signalling; AP 1; Cannabinoid; CRE; Functional selectivity; Luciferase; Transcription

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 [1 (3 DIMETHYLAMINOPROPYL) 3 INDOLYL] 3 (3 INDOLYL)MALEIMIDE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; CHELERYTHRINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; DEXANABINOL; FORSKOLIN; ISOBUTYLMETHYLXANTHINE; KT 5720; LUCIFERASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N [2 (4 BROMOCINNAMYLAMINO)ETHYL] 5 ISOQUINOLINESULFONAMIDE; PERTUSSIS TOXIN; PHORBOL 13 ACETATE 12 MYRISTATE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE C INHIBITOR; RIMONABANT; TRANSCRIPTION FACTOR AP 1; UO 126; WORTMANNIN;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLIC AMP RESPONSIVE ELEMENT; ENHANCER REGION; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR GENE; TRANSCRIPTION REGULATION;

ANIMALS; CELL LINE, TUMOR; CYCLIC AMP; CYCLOHEXANOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENHANCER ELEMENTS, GENETIC; GENES, REPORTER; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; LUCIFERASES, RENILLA; MICE; PROTEIN KINASE INHIBITORS; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; TETRAHYDROCANNABINOL; TRANSCRIPTION FACTOR AP-1; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 50249177582     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.230     Document Type: Article

References (42)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to receptors and channels (GRAC), 3rd edn. Br J Pharmacol 153 (Suppl 2): S1-S209.
2. Bash R, Rubovitch V, Gafni M, Sarne Y (2003). The stimulatory effect of cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and cAMP formation. Neurosignals 12: 39-44.
3. Bonhaus DW, Chang LK, Kwan J, Martin GR (1998). Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J Pharmacol Exp Ther 287: 884-888.
4. Bosier B, Hermans E (2007). Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance. Trends Pharmacol Sci 28: 438-446.
5. Bosier B, Tilleux S, Najimi M, Lambert DM, Hermans E (2007). Agonist selective modulation of tyrosine hydroxylase expression by cannabinoid ligands in a murine neuroblastoma cell line. J Neurochem 102: 1996-2007.
6. Bouaboula M, Poinot-Chazel C, Bourrie B, Canat X, Calandra B, Rinaldi-Carmona M et al. (1995). Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312 (Part 2): 637-641.
7. Calandra B, Portier M, Kerneis A, Delpech M, Carillon C, Le Fur G et al. (1999). Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor. Eur J Pharmacol 374: 445-455.
8. Casu MA, Pisu C, Sanna A, Tambaro S, Spada GP, Mongeau R et al. (2005). Effect of delta9-tetrahydrocannabinol on phosphorylated CREB in rat cerebellum: an immunohistochemical study. Brain Res 1048: 41-47.
9. Condie R, Herring A, Koh WS, Lee M, Kaminski NE (1996). Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J Biol Chem 271: 13175-13183.
10. Faubert BL, Kaminski NE (2000). AP-1 activity is negatively regulated by cannabinol through inhibition of its protein components, c-fos and c-jun. J Leukoc Biol 67: 259-266.
11. Giuliano M, Calvaruso G, Pellerito O, Portanova P, Carlisi D, Vento R et al. (2006). Anandamide-induced apoptosis in Chang liver cells involves ceramide and JNK/AP-1 pathway. Int J Mol Med 17: 811-819.
12. s linkage to the CB1 receptor. J Neurosci 17: 5327-5333.
13. Glass M, Northup JK (1999). Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol Pharmacol 56: 1362-1369.
14. Hampson RE, Mu J, Deadwyler SA (2000). Cannabinoid and kappa opioid receptors reduce potassium K current via activation of G(s) proteins in cultured hippocampal neurons. J Neurophysiol 84: 2356-2364.
15. Herring AC, Faubert Kaplan BL, Kaminski NE (2001). Modulation of CREB and NF-kappaB signal transduction by cannabinol in activated thymocytes. Cell Signal 13: 241-250.
16. Herring AC, Koh WS, Kaminski NE (1998). Inhibition of the cyclic AMP signaling cascade and nuclear factor binding to CRE and kappaB elements by cannabinol, a minimally CNS-active cannabinoid. Biochem Pharmacol 55: 1013-1023.
17. Ho BY, Uezono Y, Takada S, Takase I, Izumi F (1999). Coupling of the expressed cannabinoid CB1 and CB2 receptors to phospholipase C and G protein-coupled inwardly rectifying K+ channels. Receptors Channels 6: 363-374.
18. Jarrahian A, Watts VJ, Barker EL (2004). D2 dopamine receptors modulate Gα-subunit coupling of the CB1 cannabinoid receptor. J Pharmacol Exp Ther 308: 880-886.
19. Kim KS, Park DH, Wessel TC, Song B, Wagner JA, Joh TH (1993). A dual role for the cAMP-dependent protein kinase in tyrosine hydroxylase gene expression. Proc Natl Acad Sci USA 90: 3471-3475.
20. Koh WS, Crawford RB, Kaminski NE (1997). Inhibition of protein kinase A and cyclic AMP response element (CRE)-specific transcription factor binding by delta9-tetrahydrocannabinol (delta9-THC): a putative mechanism of cannabinoid-induced immune modulation. Biochem Pharmacol 53: 1477-1484.
21. Lauckner JE, Hille B, Mackie K (2005). The cannabinoid agonist WIN55212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci USA 102: 19144-19149.
22. Lewis-Tuffin LJ, Quinn PG, Chikaraishi DM (2004). Tyrosine hydroxylase transcription depends primarily on cAMP response element activity, regardless of the type of inducing stimulus. Mol Cell Neurosci 25: 536-547.
23. Maccarrone M, Di Rienzo M, Battista N, Gasperi V, Guerrieri P, Rossi A et al. (2003). The endocannabinoid system in human keratinocytes. Evidence that anandamide inhibits epidermal differentiation through CB1 receptor-dependent inhibition of protein kinase C, activation protein-1, and transglutaminase. J Biol Chem 278: 33896-33903.
24. Mackie K, Hille B (1992). Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci USA 89: 3825-3829.
25. Mackie K, Lai Y, Westenbroek R, Mitchell R (1995). Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15: 6552-6561.
26. Maneuf YP, Brotchie JM (1997). Paradoxical action of the cannabinoid WIN 55,212-2 in stimulated and basal cyclic AMP accumulation in rat globus pallidus slices. Br J Pharmacol 120: 1397-1398.
27. McIntosh BT, Hudson B, Yegorova S, Jollimore CA, Kelly ME (2007). Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells. Br J Pharmacol 152: 1111-1120.
28. i protein interactions. Mol Pharmacol 67: 2016-2024.
29. Murphy MG, Byczko Z (1989). Effects of adenosine analogues on basal, prostaglandin E1- and forskolin-stimulated cyclic AMP formation in intact neuroblastoma cells. Biochem Pharmacol 38: 3289-3295.
30. Najimi M, Robert JJ, Mallet J, Rostene W, Forgez P (2002). Neurotensin induces tyrosine hydroxylase gene activation through nitric oxide and protein kinase C signaling pathways. Mol Pharmacol 62: 647-653.
31. Ouyang Y, Hwang SG, Han SH, Kaminski NE (1998). Suppression of interleukin-2 by the putative endogenous cannabinoid 2-arachidonyl-glycerol is mediated through down-regulation of the nuclear factor of activated T cells. Mol Pharmacol 53: 676-683.
32. Pertwee RG (1999). Pharmacology of cannabinoid receptor ligands. Curr Med Chem 6: 635-664.
33. Pierreux CE, Urso B, De Meyts P, Rousseau GG, Lemaigre FP (1998). Inhibition by insulin of glucocorticoid-induced gene transcription: involvement of the ligand-binding domain of the glucocorticoid receptor and independence from the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. Mol Endocrinol 12: 1343-1354.
34. Porcella A, Gessa GL, Pani L (1998). Delta9-tetrahydrocannabinol increases sequence-specific AP-1 DNA-binding activity and Fos-related antigens in the rat brain. Eur J Neurosci 10: 1743-1751.
35. Prather PL, Martin NA, Breivogel CS, Childers SR (2000). Activation of cannabinoid receptors in rat brain by WIN 55212-2 produces coupling to multiple G protein alpha-subunits with different potencies. Mol Pharmacol 57: 1000-1010.
36. Rubino T, Sala M, Vigano D, Braida D, Castiglioni C, Limonta V et al. (2007). Cellular mechanisms underlying the anxiolytic effect of low doses of peripheral Delta9-tetrahydrocannabinol in rats. Neuropsychopharmacology 32: 2036-2045.
37. Rubovitch V, Gafni M, Sarne Y (2002). The cannabinoid agonist DALN positively modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma cells. Brain Res Mol Brain Res 101: 93-102.
38. Rueda D, Galve-Roperh I, Haro A, Guzman M (2000). The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol Pharmacol 58: 814-820.
39. Stenstrom S, Seppala M, Pfenning M, Richelson E (1985). Inhibition by ethanol of forskolin-stimulated adenylate cyclase in a murine neuroblastoma clone (N1E-115). Biochem Pharmacol 34: 3655-3659.
40. 2+ transient in NG108-15 cells. J Biochem (Tokyo) 122: 890-895.
41. 2+ in neuroblastoma x glioma hybrid NG108-15 cells. Biochem Biophys Res Commun 229: 58-64.
42. Zhao Q, He Z, Chen N, Cho YY, Zhu F, Lu C et al. (2005). 2-Arachidonoylglycerol stimulates activator protein-1-dependent transcriptional activity and enhances epidermal growth factor-induced cell transformation in JB6 P+ cells. J Biol Chem 280: 26735-26742.